Literature DB >> 8166946

Secretory immunity in the female reproductive tract.

W H Kutteh1, J Mestecky.   

Abstract

PROBLEM: Antibodies and antibody-producing cells display a different and characteristic distribution in body fluids and tissues.
METHOD: We have investigated the tissues of the female reproductive tract to determine whether the distribution of immunoglobulin-producing cells and the contents of cervical secretions were similar to those found in tissues of the secretory immune system.
RESULTS: Immunohistochemical examinations of female genital tissues revealed the presence of plasma cells that secrete IgA (and in lower numbers IgM and IgG) especially in the subepithelial layers of the uterine endo- and ectocervix, fallopian tubes, and vagina. Both IgA1- and IgA2-producing plasma cells were found in approximately equal proportions. The presence of J-chain in the IgA-secreting cells suggests the synthesis of polymeric IgA (pIgA). Epithelial cells lining the fallopian tube and endocervix were positive for secretory component (SC), which is required for the transepithelial transport of pIgA into external secretions. Cervical mucus was collected and the molecular forms of IgA were separated using column chromatography. Approximately 80% of IgA in cervical mucus was polymeric compared with 55% in the vaginal fluid.
CONCLUSIONS: These data indicate that all effector components of the mucosal immune system are present in the female reproductive tract. The immunization routes that lead to a secretory IgA (S-IgA) response need to be further explored.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166946     DOI: 10.1111/j.1600-0897.1994.tb00845.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  20 in total

1.  Generation of female genital tract antibody responses by local or central (common) mucosal immunization.

Authors:  H Y Wu; S Abdu; D Stinson; M W Russell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans.

Authors:  A Rudin; E L Johansson; C Bergquist; J Holmgren
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

3.  Immunization of the female genital tract with a DNA-based vaccine.

Authors:  J B Livingston; S Lu; H Robinson; D J Anderson
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

4.  Comparison of cervicovaginal humoral immunity in clinically asymptomatic (CDC A1 and A2 category) patients with HIV-1 and HIV-2 infection.

Authors:  L Bélec; C Tévi-Bénissan; T Dupré; A S Mohamed; T Prazuck; J Gilquin; J M Kanga; J Pillot
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

Review 5.  Assessing mucosal humoral immunity.

Authors:  S J Challacombe
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

6.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

7.  Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.

Authors:  Zili Li; Senthilkumar Palaniyandi; Rongyu Zeng; Wenbin Tuo; Derry C Roopenian; Xiaoping Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

Review 8.  Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections.

Authors:  D K Hickey; M V Patel; J V Fahey; C R Wira
Journal:  J Reprod Immunol       Date:  2011-02-26       Impact factor: 4.054

9.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 10.  Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.

Authors:  J Mestecky; S Jackson
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.